Nasal Glucagon + Oxymetazoline

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Common Cold

Conditions

Common Cold

Trial Timeline

Mar 1, 2013 → Apr 1, 2013

About Nasal Glucagon + Oxymetazoline

Nasal Glucagon + Oxymetazoline is a phase 1 stage product being developed by Eli Lilly for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT02778100. Target conditions include Common Cold.

What happened to similar drugs?

5 of 17 similar drugs in Common Cold were approved

Approved (5) Terminated (3) Active (10)

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02778100Phase 1Completed